Drug-induced liver injury (DILI) has been observed in patients with multiple sclerosis (MS), raising concerns on the liver safety of MS drugs.
Objective:
To describe DILI events with MS drugs by analyzing the FDA Adverse Event Reporting System.
Methods:
DILI reports were extracted and classified in overall liver injury (OLI), including asymptomatic elevation of liver enzymes, and severe liver injury (SLI). We performed disproportionality analysis by calculating adjusted reporting odds ratios (RORs) with 95% confidence interval (CI) and case-by-case evaluation for concomitant drugs with hepatotoxic potential.
Results:
Fampridine showed statistically significant ROR for both OLI and SLI, whereas teriflunomide and fingolimod generated solid disproportionality (ROR > 2) only for OLI (ROR, 2.31; 95% CI, 2.12–2.52; and 2.53; 2.40–2.66, respectively). Among monoclonal antibodies, only alemtuzumab generated higher-than-expected ROR for OLI (1.34; 1.09–1.65). We also detected the expected hepatotoxic potential of beta interferon and mitoxantrone. Concomitant reporting of hepatotoxic drugs ranged from 26% (dimethyl fumarate) to 90% (mitoxantrone).
Conclusion:
These real-world pharmacovigilance findings suggest that DILI might be a common feature of MS drugs and call for (1) formal population-based study to verify the risk of fampridine and (2) awareness by clinicians, who should assess the possible responsibility of MS drugs when they diagnose DILI.
ComiGRadaelliMSoelberg SorensenP.Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet2017; 389: 1347–1356.
2.
OnakpoyaIJHeneghanCJAronsonJK.Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med2016; 14: 10.
3.
LewisJH.The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol2015; 13: 2173–2189.e8.
4.
MunozMAKulickCGKortepeterCM, et al. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler2017; 23: 1947–1949.
5.
AlmeidaJSola-VallsNPoseE, et al. Liver injury and glatiramer acetate, an uncommon association: Case report and literature review. Ther Adv Neurol Disord2017; 10: 367–372.
6.
AntezanaAHerbertJParkJ, et al. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS. Neurology2014; 82: 1846–1847.
7.
OnmezAEminlerATErgencH, et al. Drug-induced liver injury by glatiramer acetate used for treatment of multiple sclerosis: A case report. J Investig Med High Impact Case Rep2013; 1: 2324709613517493.
BjornssonESHoofnagleJH.Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology2016; 63: 590–603.
10.
BrinkerADLyndlyJTonningJ, et al. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Drug Saf2013; 36: 1169–1178.
RaschiEPoluzziESalvoF, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis2018; 28: 533–542.
MontastrucJLSommetABagheriH, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol2011; 72: 905–908.
15.
RaschiEPoluzziEKociA, et al. Liver injury with novel oral anticoagulants: Assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol2015; 80: 285–293.
16.
SuzukiAAndradeRJBjornssonE, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: Unified list based on international collaborative work. Drug Saf2010; 33: 503–522.
17.
RaschiEDe PontiF.Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol2015; 7: 1761–1771.
18.
RaschiEPoluzziEKociA, et al. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol2014; 6: 601–612.
19.
BernalWWendonJ.Acute liver failure. N Engl J Med2013; 369: 2525–2534.
20.
National Institutes of Health (NIH). LiverTox: Clinical and research information on drug-induced liver injury, https://livertox.nih.gov/ (accessed 25 July 2018).
21.
WuZHanMChenT, et al. Acute liver failure: Mechanisms of immune-mediated liver injury. Liver Int2010; 30: 782–794.
22.
RothRAMaiuriARGaneyPE.Idiosyncratic drug-induced liver injury: Is drug-cytokine interaction the linchpin?J Pharmacol Exp Ther2017; 360: 461–470.
FrejoMTDel PinoJLoboM, et al. Liver and kidney damage induced by 4-aminopyridine in a repeated dose (28 days) oral toxicity study in rats: Gene expression profile of hybrid cell death. Toxicol Lett2014; 225: 252–263.
25.
NeumannHCsepregiASailerM, et al. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis. J Neurol2007; 254: 816–817.
26.
MakhaniNNganBYKamathBM, et al. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS. Neurology2013; 81: 850–852.
27.
BezabehSFlowersCMKortepeterC, et al. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther2010; 31: 1028–1035.
28.
AntezanaASigalSHerbertJ, et al. Natalizumab-induced hepatic injury: A case report and review of literature. Mult Scler Relat Disord2015; 4: 495–498.
29.
JungstCKimYJLammertF.Severe drug-induced liver injury related to therapy with dimethyl fumarate. Hepatology2016; 64: 1367–1369.
30.
ScalfaroEStreefkerkHJMerzM, et al. Preliminary results of a novel algorithmic method aiming to support initial causality assessment of routine pharmacovigilance case reports for medication-induced liver injury: The PV-RUCAM. Drug Saf2017; 40: 715–727.
31.
HoffmanKBDemakasARDimbilM, et al. Stimulated reporting: The impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf2014; 37: 971–980.
32.
HoffmanKBDimbilMErdmanCB, et al. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf2014; 37: 283–294.
